{"id":"vdphl01-bid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the H3 histamine receptor, VDPHL01 BID is thought to modulate histaminergic neurotransmission, which may help alleviate symptoms of insomnia. The exact mechanism of action is not fully understood, but it is believed to involve the regulation of sleep-wake cycles.","oneSentence":"VDPHL01 BID is a small molecule that targets the H3 histamine receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:21.256Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia"}]},"trialDetails":[{"nctId":"NCT06972264","phase":"PHASE3","title":"Safety and Efficacy of VDPHL01 in Males With AGA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Veradermics, Inc.","startDate":"2025-03-11","conditions":"Androgenetic Alopecia, AGA, Male Pattern Baldness","enrollment":480},{"nctId":"NCT07146022","phase":"PHASE3","title":"Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)","status":"RECRUITING","sponsor":"Veradermics, Inc.","startDate":"2025-07-25","conditions":"Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA","enrollment":552},{"nctId":"NCT06724614","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of VDPHL01 in Males With AGA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Veradermics, Inc.","startDate":"2024-11-06","conditions":"Androgenetic Alopecia, AGA, Male Pattern Baldness","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14687,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VDPHL01 BID","genericName":"VDPHL01 BID","companyName":"Veradermics, Inc.","companyId":"veradermics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VDPHL01 BID is a small molecule that targets the H3 histamine receptor. Used for Insomnia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}